STOCK TITAN

Citadel entities and Kenneth Griffin (SPRB) report 1.9% beneficial stake in Spruce

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Citadel-affiliated entities and Kenneth Griffin report a sub‑5% passive stake in Spruce Biosciences, Inc. They may be deemed to beneficially own various blocks of common stock, with Mr. Griffin associated with 51,919 Shares, representing 1.9% of Spruce’s common stock outstanding.

The reported percentages are based on 2,752,278 Shares outstanding as of May 11, 2026, as referenced from Spruce’s Form 10‑Q. All reporting persons disclose no sole voting or dispositive power, only shared voting and dispositive power over their respective share amounts, and confirm ownership of 5 percent or less of the class.

Positive

  • None.

Negative

  • None.
Mr. Griffin beneficial ownership 51,919 Shares Common stock of Spruce Biosciences that Mr. Griffin may be deemed to beneficially own
Mr. Griffin percent of class 1.9% Percentage of Spruce Biosciences Shares outstanding associated with Mr. Griffin
Citadel Advisors-related holdings 46,960 Shares Shares each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own
Citadel Advisors percent of class 1.7% Percent of outstanding Shares for each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
Citadel Securities holdings 1,684 Shares Spruce Biosciences Shares Citadel Securities LLC may be deemed to beneficially own
Citadel Securities Group holdings 4,959 Shares Spruce Biosciences Shares each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own
Shares outstanding basis 2,752,278 Shares Spruce Biosciences Shares outstanding as of May 11, 2026, used to compute ownership percentages
beneficially own financial
"may be deemed to beneficially own 46,960 Shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting power financial
"Shared Voting Power 46,960.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
dispositive power financial
"Shared Dispositive Power 51,919.00"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
attorney-in-fact regulatory
"Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What stake in Spruce Biosciences (SPRB) is associated with Kenneth Griffin in this Schedule 13G/A?

Kenneth Griffin may be deemed to beneficially own 51,919 Shares of Spruce Biosciences common stock, representing 1.9% of the Shares outstanding, based on 2,752,278 Shares outstanding as of May 11, 2026.

How many Spruce Biosciences (SPRB) shares does Citadel Advisors LLC report in this filing?

Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 46,960 Shares of Spruce Biosciences, which constitutes 1.7% of the Shares outstanding, with only shared voting and dispositive power over those Shares.

What is the reported ownership percentage of Citadel Securities LLC in Spruce Biosciences (SPRB)?

Citadel Securities LLC may be deemed to beneficially own 1,684 Shares of Spruce Biosciences, representing 0.1% of the Shares outstanding, and has shared voting and dispositive power over those Shares, with no sole voting or dispositive power.

Does this Schedule 13G/A show Citadel owning more than 5% of Spruce Biosciences (SPRB)?

No. The reporting persons state ownership of 5 percent or less of Spruce Biosciences’ common stock. Mr. Griffin’s deemed beneficial ownership is 1.9% of the outstanding Shares, and other Citadel entities report smaller percentages of the class.

What share count did the Citadel filers use to calculate their ownership in Spruce Biosciences (SPRB)?

The ownership percentages are based on 2,752,278 Shares outstanding of Spruce Biosciences as of May 11, 2026, according to the issuer’s Form 10‑Q filed on May 13, 2026, as referenced by the reporting persons.

Do Citadel and Kenneth Griffin report sole or shared voting power over Spruce Biosciences (SPRB) shares?

They report zero sole voting or dispositive power over Spruce Biosciences Shares. All reported positions, including Mr. Griffin’s 51,919 Shares, reflect only shared voting and shared dispositive power with the relevant affiliated entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





85209E208

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 2,752,278 Shares outstanding as of May 11, 2026 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 13, 2026).


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:08/14/2026

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.